Advertisement

Cardiovascular Drugs and Therapy

, Volume 1, Issue 1, pp 51–55 | Cite as

Converting enzyme inhibitors (captopril, enalapril, perindopril) prevent early-post infarction ventricular fibrillation in the anaesthetized rat

  • C. Ribuot
  • L. Rochette
Focussed Section: ACE Inhibitors

Summary

The angiotensin-converting enzyme inhibitors, captopril, enalapril and perindopril, exert antiarrhythmic effects on early post-infarction arrhythmias in anaesthetized rats. These studies support the hypothesis that converting enzyme inhibitors could have a “cardioprotective” effect, but the doses used are probably “high” in relation to those therapeutically applicable to man.

Key words

converting enzyme inhibitors antiarrhythmic effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cody RJ. Haemodynamic responses to specific reninangiotensin inhibitors in hypertension and congestive heart failure. A review.Drugs 1984; 28:144–69.Google Scholar
  2. 2.
    Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor.Circulation 1982; 65:40–48.Google Scholar
  3. 3.
    Lefer AM, Peck RC. Cardioprotective effects of enalapril in acute myocardial ischemia.Pharmacology 1984; 29:61–69.Google Scholar
  4. 4.
    Hock CE, Ribeiro LGT, Lefer AM. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction.Am Heart J 1985; 109:222–28.Google Scholar
  5. 5.
    Unger T, Ganten D, Lang LE, Scholkens BA. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, HOE 498 and MK 421, in spontaneously hypertensive rats.J Cardiovasc Pharmacol 1984; 6:872–80.Google Scholar
  6. 6.
    Laubie M, Schiavi P, Vincent M, Schmitt H. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in haemodynamic effects.J Cardiovasc Pharmacol 1984; 6:1076–82.Google Scholar
  7. 7.
    Clark C, Foreman MI, Kane KA, et al. Coronary artery ligation in anaesthetized rats as a method for the production of experimental dysrhythmias and for the determination of infarct size.J Pharmacol Method 1980; 3:357–68.Google Scholar
  8. 8.
    Selye H, Bajusz E, Grasso S, Mendell P. Simple techniques for the surgical occlusion of coronary vessels in the rat.Angiology 1960; 11:398–407.Google Scholar
  9. 9.
    Fagbemi O, Parratt JR. Calcium antagonists prevent post-infarction ventricular fibrillation.Eur J Pharmacol 1981; 75:179–85.Google Scholar
  10. 10.
    Van Gilst WH, De Graeff A, Kingma JH, et al. Captopril reduces purine loss and reperfusion arrhythmias in the rat heart after coronary artery occlusion.Eur J Pharmacol 1984; 100:113–17.Google Scholar
  11. 11.
    De Graeff A, Van Gilst WH, De Langen CDJ, et al. Concentration-dependent protection by captopril against ischemia-reperfusion injury in the isolated rat heart.Arch Int Pharmacodyn 1986; 280:181–93.Google Scholar
  12. 12.
    Van Gilst WH, De Graeff PA, Wesseling H, De Langen CDJ. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril and HOE 498.J Cardiovasc Pharmacol 1986; 8:722–28.Google Scholar
  13. 13.
    Rochette L, Ribuot C, Belichard P, Bril A. Angiotensin converting enzyme inhibitors (captopril, perindopril) reduce ventricular arrhythmias induced by myocardial ischemia and reperfusion in rats.J Mol Cell Cardiol 1986; 18(Suppl 2):44.Google Scholar
  14. 14.
    Daniell HB, Carson RR, Ballard KD, et al. Effects of captopril on limiting infarct size in conscious dogs.J Cardiovasc Pharmacol 1984; 6:1043–47.Google Scholar
  15. 15.
    Michel JB, Dussaule JC, Alhenc-Gelas F, et al. Can inhibition of the renin-angiotensin system have a cardioprotective effect?J Cardiovasc Pharmacol 1985; 7:S75-S79.Google Scholar
  16. 16.
    Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients.J Cardiovasc Pharmacol 1985; 7:S52-S55.Google Scholar
  17. 17.
    Ziogas J, Story DF, Rand MJ. Effects of locally generated angiotensin II on noradrenergic transmission in guinea-pig isolated atria.Eur J Pharmacol 1984; 106:11–18.Google Scholar
  18. 18.
    Dusing R, Scherhag R, Landsberg G, et al. The converting enzyme inhibitor captopril stimulates prostacyclin synthesis by isolated rat aorta.Eur J Pharmacol 1983; 91:501–4.Google Scholar
  19. 19.
    Vane JR. Prostaglandins and the cardiovascular system.Br Heart J 1983; 49:405–9.Google Scholar
  20. 20.
    Rademaker M, Shaw TRD, Williams BC, et al. Intravenous captopril treatment in patients with severe cardiac failure.Br Heart J 1986; 55:187–90.Google Scholar

Copyright information

© Martinus Nijhoff Publishing 1987

Authors and Affiliations

  • C. Ribuot
    • 1
  • L. Rochette
  1. 1.Laboratoire de Pharmacodynamie et de Physiologie PharmaceutiqueFaculté de Pharmacie-Université de DIJON-7 Bd. J.d'Arc 21000DijonFrance

Personalised recommendations